Cartesian Therapeutics
Clinical trials sponsored by Cartesian Therapeutics, explained in plain language.
Cartesian Therapeutics
RNAC
NASDAQ
A clinical-stage biotech developing RNA cell therapies for autoimmune diseases.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Engineered immune cells take on lupus in tiny trial Results expected Dec 2026 (estimated)
- Could a One-Time cell therapy ease myasthenia gravis? new trial launches Results expected Dec 2026 (estimated) 🚀 Make-or-break